A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia (CLL2P)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01558167|
Recruitment Status : Completed
First Posted : March 20, 2012
Last Update Posted : May 15, 2018
This is a prospective, multicenter, open label, non-randomized, phase I/II-study to define safety and efficacy of BRL combination in relapsed/refractory patients and to recommend a safe and efficacious dose for future phase II/III study.
Hypothesis: The simultaneous administration of BRL in relapsed CLL is feasible, safe and efficient.
|Condition or disease||Intervention/treatment||Phase|
|Chronic Lymphocytic Leukemia||Drug: Bendamustine, Rituximab, Lenalidomide||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||22 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A phaseI/II Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide (BRL) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|
|Study Start Date :||February 2011|
|Actual Primary Completion Date :||October 2013|
|Actual Study Completion Date :||June 2015|
Experimental: Bendamustine, Rituximab,Lenalidomide
Dose modification treatment plan of lenalidomide
Drug: Bendamustine, Rituximab, Lenalidomide
Bendamustine: 50 mg/m2, i.v., day 1+2
Rituximab: Cycle 1: 375 mg/m2, i.v. day 0; Cycle 2-6: 500mg/m2, i.v., day 1
- dose limiting toxicity [ Time Frame: After 28 days of dosing at the respective target dose level of lenalidomide ]
DLT defined as
- absolute neutrophil count < 500/µl for 7 consecutive days or more
- febrile neutropenia
- platelet count < 20.000/µl
- grade 4 tumour flare
- grade 4 non-hematologic toxicity
- Response rate [ Time Frame: up to 4 years ]response will be evaluated according to criteria of the CLL-Guidelines on CLL of the IWCLL-working Group.
- progression free survival [ Time Frame: up to 4 years ]
Progression-free survival based on investigator's assessment:
PFS is defined as the time from registration to the first occurrence of progression, relapse or death from any cause. Disease progression will be assessed by the investigators using the IWCLL criteria.
- Overall Survival [ Time Frame: up to 4 years ]Overall survival is defined as the time from registration to death.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01558167
|University Hospital of Cologne|
|Cologne, Germany, 50924|
|Study Chair:||Michael Hallek, Prof.Dr.||German CLL Study Group|
|Study Director:||Clemens Wendtner, Prof.Dr.||German CLL Study Group|